Navigation Links
Global Experts Explore Entire Spectrum of Aids Vaccine Development
Date:8/19/2007

More than 900 attendees from 47 countries convene in Seattle for AIDS

Vaccine 2007 Conference

SEATTLE, Aug. 20 /PRNewswire/ -- More than 900 global researchers, clinicians, and specialists convene this week for the AIDS Vaccine 2007 Conference at the Sheraton Seattle Hotel and Towers. Since the AIDS Vaccine 2000 Conference in Paris, this event has emerged as the premier forum for the exchange of scientific information relating to the difficult task of developing an effective vaccine against HIV.

"It has become clear that a preventive vaccine is essential to controlling the global AIDS epidemic," says conference chair Dr. Lawrence Corey. "The conference provides a venue for the full-scale international, interdisciplinary collaboration which is critical to the development of a global AIDS vaccine."

The week-long conference which concludes on Aug. 23 will examine the entire spectrum of issues in AIDS vaccine development and deployment: including, the global effort in preventative and therapeutic vaccines, the potential development of pediatric and adolescent vaccines, clinical trials in emerging countries, and the need for strong political and financial commitment to support the scientific development of a vaccine against AIDS.

The location of the conference in Seattle is reflective of the Pacific Northwest's international leadership in the development of an AIDS vaccine. Seattle organizations contributing to the conference include the Fred Hutchinson Cancer Research Center's HIV Vaccine Trials Network, the Seattle Biomedical Research Institute, the University of Washington and the Bill & Melinda Gates Foundation.

AIDS Vaccine 2007 is the first conference to be organized under the auspices of the Global HIV Vaccine Enterprise, (http://www.hivvaccineenterprise.org) an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. Additionally, at this year's conference the Enterprise will release its first comprehensive report, detailing the successes and efforts of global AIDS vaccine research over the last four years.

"By hosting the conference the Enterprise furthers its purpose to help scientists work as a global community of problem solvers in the spirit of collaboration to move the best science forward as quickly as possible," says Dr. Jose Esparza, conference co-chair and interim head of the Enterprise.

The AIDS epidemic continues to grow as a global threat with the number of people living with HIV increasing in every region of the world. According to UNAIDS, the most striking increases have occurred in East Asia, Eastern Europe, and Central Asia, where the number of people living with HIV in 2006 was over one-fifth (21%) higher than in 2004.

About the AIDS Vaccine 2007 Conference For more information about the conference or for a complete program of the day's events, please visit the AIDS Vaccine 2007 Conference website at http://www.aidsvaccine07.org.


'/>"/>
SOURCE The AIDS Vaccine 2007 Conference

Copyright©2007 PR Newswire.

Related biology technology :

1. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
2. The state of global biotech: An Ernst & Young perspective
3. Doyle announces new energy, global warming policies
4. Lucigen Corp. enters global licensing agreement
5. Global information firm reaches diverse markets
6. Work-life imbalance - A global problem getting worse
7. Leading global Big Pharma companies of 2005
8. Learning to swim in the global talent pool
9. Federal and global guidelines on stem cell research offer a level playing field
10. Midwest life-science company Perrigo globalizes under the radar
11. The global power of WWW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):